A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
Phase 3
90
about 3.6 years
18+
7 sites in AL, CA, FL +3
What this study is about
Researchers are testing a treatment called bimekizumab to see how it affects gene expression markers in people with moderate to severe plaque psoriasis. The trial will last for 1324 days and involve approximately 90 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take bimekizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
bimekizumab
Primary: Change from Baseline in composite gene expression score using reverse transcription-polymerase chain reaction (RT-PCR) in lesional skin at Week 48
Secondary: TEAEs leading to permanent discontinuation of IMP from Baseline to the end of the SFU, Treatment-emergent adverse events (TEAEs) from Baseline to the end of the Safety Follow-Up (SFU), Treatment-emergent serious adverse event (TESAEs) from Baseline to the end of the SFU
Dermatology